Category Research

Neurocrine Biosciences Reveals INGREZZA® Data: Most Achieve Tardive Dyskinesia Remission

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) showcased findings from the long-term KINECT®-4 study, revealing that nearly 60% of participants achieved remission from tardive dyskinesia after 48 weeks of treatment with once-daily INGREZZA® (valbenazine) capsules. This research, titled “Remission of Tardive Dyskinesia…

Read MoreNeurocrine Biosciences Reveals INGREZZA® Data: Most Achieve Tardive Dyskinesia Remission

Medidata and Cogstate Partner to Enhance Neurology Clinical Trials with AI Solutions

Medidata, a brand of Dassault Systèmes and a leading provider of clinical trial solutions, has partnered with Cogstate, a leader in neuroscience solutions, to transform clinical trials and outcome measurements for central nervous system (CNS) diseases, including neurodegenerative, psychiatric, motor,…

Read MoreMedidata and Cogstate Partner to Enhance Neurology Clinical Trials with AI Solutions

AbbVie Acquires Aliada Therapeutics to Strengthen Alzheimer’s and Neuroscience Commitment

AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Aliada Therapeutics, a biotechnology firm focused on developing therapies using innovative blood-brain barrier (BBB)-crossing technology aimed at treating complex central nervous system (CNS) diseases. Aliada’s lead investigational asset, ALIA-1758, is…

Read MoreAbbVie Acquires Aliada Therapeutics to Strengthen Alzheimer’s and Neuroscience Commitment

Merck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer

Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940 (mRNA-4157), an individualized neoantigen therapy (INT), combined with KEYTRUDA® (pembrolizumab),…

Read MoreMerck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer

Biogen Shares Positive Phase 2 Results for Felzartamab in IgA Nephropathy at ASN Kidney Week 2024

Biogen Inc. (Nasdaq: BIIB) shared full results from its Phase 2 IGNAZ study on felzartamab, an investigational anti-CD38 monoclonal antibody, for IgA nephropathy (IgAN) treatment. Data revealed significant reductions in proteinuria, kidney function stabilization, and sustained treatment effects over 18…

Read MoreBiogen Shares Positive Phase 2 Results for Felzartamab in IgA Nephropathy at ASN Kidney Week 2024

BioHub Maryland Launches Biopharma Workforce Training Center in Montgomery County’s Life Sciences Corridor

BioHub Maryland, an initiative aimed at accelerating the life sciences sector in the state, officially opened its new biopharmaceutical workforce training center on October 24 at 9808 Medical Center Drive in Rockville. The event featured Maryland Lt. Governor Aruna Miller…

Read MoreBioHub Maryland Launches Biopharma Workforce Training Center in Montgomery County’s Life Sciences Corridor